Research notes,
lab methods,
compound profiles.
Editorial dispatches from the NZM research desk — receptor pharmacology, protocol-design notes, lab-method walkthroughs, and frontier-science explainers. Written for researchers, in plain language.
More from the desk.
Retatrutide vs Ozempic: Research Compound vs Branded GLP-1
Ozempic is the branded prescription form of semaglutide. Retatrutide is a research-grade triple-agonist peptide. The names sit in different worlds, and the comparison researchers are usually…
PT-141: Nasal vs Injection Route Pharmacokinetics
PT-141 (bremelanotide) is studied across two delivery routes, intranasal and subcutaneous. The pharmacokinetic profiles diverge, and the choice of route is a research-design variable, not a…
Mounjaro vs Ozempic: Tirzepatide (Dual Agonist) vs Semaglutide (GLP-1)
Mounjaro and Ozempic look like sibling products but contain different molecules. Mounjaro's compound activates two incretin receptors; Ozempic's compound activates one, and that mechanism gap is…
Copper Peptides: Chemistry, Mechanism, and Dermal-Research Applications
GHK-Cu is the most-cited copper peptide in dermal-research literature, but the wider class of tripeptide-copper complexes, including AHK-Cu, is what defines the category.
Retatrutide vs Semaglutide: Triple-Agonist vs Single-Pathway GLP-1
Semaglutide engages one receptor; Retatrutide engages three. The mechanism gap is wider than the family relationship suggests, and it changes what each compound is useful for…
Wegovy vs Ozempic: Same Compound, Different Brand Identity
Wegovy and Ozempic share the same active molecule (semaglutide). They are distinct branded products with different indications and dose strengths, but the mechanism is identical.
Solid-Phase Peptide Synthesis: How Research-Grade Peptides Are Actually Made
Solid-phase peptide synthesis is the chemistry behind every research peptide in the modern catalog: how the process works, why it governs purity, and how to read…
GLP-1, GIP, and Glucagon: How Receptor Profile Shapes Research Outcomes
Single-pathway, dual, and triple agonists produce categorically different downstream effects. The receptor profile a molecule activates is the most consequential decision in any modern incretin-mimetic protocol.
Why Janoshik Analytical: A Researcher’s Guide to Independent Lab Verification
Independent third-party verification is the only credible way to certify what's actually in a research-grade peptide vial. Here's why Janoshik is the European reference, and what…